Intrastromal femtosecond laser presbyopia correction successful

Article

Using the intrastromal femtosecond laser procedure to correct presbyopia has been shown to be successful.

Using the intrastromal femtosecond laser procedure to correct presbyopia has been shown to be successful, in a recent study published in the Journal of Refractive Surgery.

The prospective multicentre, nonrandomized clinical investigation, headed by Dr Mike P. Holzner, Department of Ophthalmology, International Vision Correction Research Centre, University of Heidelberg, Germany, included 63 presbyopic patients with mild hyperopia.

The procedure was performed using a femtosecond laser in the non-dominant eye and conducting near and distance visual acuity tests, slit-lamp examinations, and corneal topography. Follow-up was completed at 1 day, 1 week, and 1, 3, 6, and 12 months post-op for each patient.

Median uncorrected distance visual acuity and corrected distance visual acuity (CDVA) remained stable at 0.1 logMAR and 0.0 logMAR, respectively. Median spherical equivalent changed from +0.63 D before surgery to 0.00 D after surgery.

Preoperatively, median uncorrected near visual acuity was 0.7 logMAR but increased to 0.2 logMAR postoperatively. Eyes gained an average of 4 lines, but a loss of 2 lines of CDVA was seen in 7.1% of eyes.

The procedure demonstrated stable visual outcomes over a one year follow-up. Patient satisfaction was very high at 80%, with short treatment time and corneal surface integrity being major benefits of the procedure.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.